The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.
This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.
Dr. Mikhail Kosiborod is a cardiologist, the Vice President of Research at Saint Luke’s Health System, Executive Director of the Cardiometabolic Center Alliance, Director of Cardiometabolic Research and Co-Director of the Haverty Cardiometabolic Center of Excellence at Saint Luke’s Mid America Heart Institute, Professor of Medicine at the University of Missouri-Kansas City and the inaugural recipient of the Ben McCallister, MD Endowed Chair in Cardiovascular Research at Saint Luke’s Health System. Dr. Kosiborod received training in clinical research, epidemiology and health policy through the Robert Wood Johnson Clinical Scholars Program, as well as clinical training in cardiovascular medicine at Yale University School of Medicine. He is an internationally recognized expert in cardiometabolic medicine. Dr. Kosiborod has authored and co-authored over 300 peer-reviewed publications, including scientific statements and position documents. He is involved in the leadership of multiple clinical trials and multi-center registries.
Professor Mark Petrie MD, FRCP
Institute of Cardiovascular & Medical Sciences, University of Glasgow, Glasgow, UK
Mark Petrie is a Professor of Cardiology in the Institute of Cardiovascular and Medical Sciences at the University of Glasgow, and a cardiologist at Glasgow Royal Infirmary, UK. Professor Petrie has a high-volume clinical practice within a large heart failure team. His research interests focus on diabetes and cardiovascular disease, intervention in heart failure, subcutaneous furosemide in heart failure, revascularisation in heart failure, peripartum cardiomyopathy, microvascular disease in heart failure with preserved ejection fraction, cardiac remodelling, iron in heart failure and cardio-oncology. He has leadership roles in many trials including STICH, REVIVED, DAPA-HF, EMPACT-MI, STEP-HFpEF, REALIZE-K, IRONMAN, PARADISE-MI and has chaired or been a member of over 40 Clinical Events Committees for major trials. Mark has published over 220 original publications, many in high impact factor journals such as NEJM, Lancet, JAMA, Circulation and JACC.
Professor Peter van der Meer, MD, PhD
UMCG Cardiology research institute, Groningen, UThe Netherlands
Peter van der Meer received both his MD and PhD cum laude from the University of Groningen in the Netherlands. He is trained as a cardiologist with a focus on heart failure and cardiac devices. He did a postdoctoral fellowship at Harvard Medical School with prof. Ken Chien to further train his skills in cardiac stem cell biology.
The group of Prof. Van der Meer consists of PhD students, technicians and post-docs with various backgrounds (biologists, medical doctors, and biomedical-engineers) working on translational research topics to bridge the gap between bench and bedside. His group focuses on understanding the susceptibility to develop heart failure and exploring novel treatment targets and therapies. He is a member of several steering committees of large morbidity and mortality trials investigating the impact of new and old drugs in patients with heart failure, including digoxin and iron.